NPA To Supreme Court: Risk-Benefit Standard Would “Unravel” DSHEA
This article was originally published in The Tan Sheet
Executive Summary
The National Products Association filed a brief with the Supreme Court April 6 in support of Nutraceutical Corp.'s petition for review of an appellate court decision upholding FDA's use of a risk-benefit standard to determine product adulteration
You may also be interested in...
Kratom Action Presents Regulatory Puzzle For FDA
The agency is seizing imports of kratom but industry seeks to clarify whether the substance, which in large doses can have narcotic effects, can be used in dietary supplements. Because FDA acknowledges kratom is a dietary ingredient, a ban as used for ephedra action may be up for consideration.
Kratom Action Presents Regulatory Puzzle For FDA
The agency is seizing imports of kratom but industry seeks to clarify whether the substance, which in large doses can have narcotic effects, can be used in dietary supplements. Because FDA acknowledges kratom is a dietary ingredient, a ban as used for ephedra action may be up for consideration.
Supreme Court Refuses Ephedra Case, Battle Against Risk-Benefit Continues
Challenges to the risk-benefit analysis FDA applied in banning the use of ephedra will continue following the Supreme Court's May 14 refusal to hear Nutraceutical Corp.'s appeal, according to the firm's attorney and to industry trade groups